Medical management of obesity: Present and future therapy

Journal of Gastrointestinal Surgery

Volumn 7, Issue 4, 2003, Pages 464-467

  Klein, Samuel ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMFEPRAMONE; AMYLIN; ANOREXIGENIC AGENT; APOLIPOPROTEIN A4; BENZPHETAMINE; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; BOMBESIN; CANNABINOID RECEPTOR ANTAGONIST; ENTEROSTATIN; ENZYME INHIBITOR; GASTROINTESTINAL HORMONE; GLUCAGON LIKE PEPTIDE 1; MAZINDOL; MELANOCORTIN 4 RECEPTOR; METHAMPHETAMINE; OBY TRIM; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHENDIMETRAZINE TARTRATE; PHENTERMINE; PHENTERMINE RESIN; PRELU 2; PROTEIN INHIBITOR; RECOMBINANT CILIARY NEUROTROPHIC FACTOR; RECOMBINANT LEPTIN; RECOMBINANT PROTEIN; SEROTONIN ANTAGONIST; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE; TRIACYLGLYCEROL LIPASE; UNINDEXED DRUG; X TROZINE;

BLOOD PRESSURE; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; DEFECATION DISORDER; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; FECES; FECES ANALYSIS; FECES INCONTINENCE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTENSION; INSOMNIA; OBESITY; SIDE EFFECT; WEIGHT REDUCTION; XEROSTOMIA;

EID: 0038638324     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1091-255X(03)00049-0     Document Type: Conference Paper

References (21)

1. Sjöström L., Rissanen A., Andersen T., et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet. 352:1998;167-172.
2. James W.P.T., Astrup A., Finer N., et al. Effect of sibutramine on weight maintenance after weight loss: A randomised trial. Lancet. 356:2000;2119-2125.
3. Wadden T.A., Berkowitz R.I., Sarwer D.B., et al. Benefits of lifestyle modification in the pharmacologic treatment of obesity: A randomized trial. Arch Intern Med. 161:2001;218-227.
4. Bray G.A., Blackburn G.L., Ferguson J.M., et al. Sibutramine produces dose-related weight loss. Obes Res. 7:1999;189-198.
5. National Institutes of Health, National Heart, Lung and Blood Institute, and North American Association for the Study of Obesity. Practical Guide to the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults; October 2000. NIH Publication No. 00-4084.
6. McMahon F.G., Fujioka K., Singh B.N., et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: A 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med. 160:2000;2185-2191.
7. Smith I.G., Goulder M.A. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Prac. 50:2001;505-512.
8. Wirth A., Krause J. Long-term weight loss with sibutramine. A randomized controlled trial. JAMA. 286:2001;1331-1339.
9. Apfelbaum M., Vague P., Ziegler O., et al. Long-term maintenance of weight loss after a very-low-calorie diet: A randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med. 106:1999;179-184.
10. Hadvary P., Lengsfield H., Wolfer H. Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin. Biochem J. 256:1998;357-361.
11. Zhi J., Melia A.T., Guerciolini R., et al. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther. 56:1994;82-86.
12. Davidson M.H., Hauptman J., DiGirolamo M., et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. JAMA. 281:1999;235-242.
13. Rössner S., Sjöström L., Noack R., et al. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obes Res. 8:2000;49-61.
14. Finer N., James W.P., Kopelman P.G., et al. One-year treatment of obesity: A randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord. 24:2000;306-313.
15. Hauptman J., Lucas C., Boldrin M.N., et al. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med. 9:2000;160-167.
16. Hollander P.A., Elbein S.C., Hirsch I.B., et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. Diabetes Care. 21:1998;1288-1294.
17. Lindgarde F. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity Study. J Intern Med. 248:2000;245-254.
18. Cavaliere H., Floriano I., Medeiros-Neto G. Gastrointestinal side-effects of orlistat by concomitant prescription of natural fibers (psyllium mucilloid). Int J Obes Relat Metab Disord. 25:2001;1095-1099.
19. Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord. 21:(Suppl 3):1997;S12-S23.
20. Colman E., Fossler M. Reduction in blood cyclosporin concentrations by orlistat. N Engl J Med. 342:2000;1141-1142.
21. Schnetzler B., Kondo-Oestreicher M., Vala D. Orlistat decreases the plasma level of cyclosporine and may be responsible for the development of acute rejection episodes. Transplantation. 70:2000;1540-1541.